Eintrag weiter verarbeiten
Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , |
| In: | Journal of Clinical Oncology, 24, 2006, 18_suppl, S. 7575-7575 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Kim, Y. K. Kim, H. N. Lee, J. J. Yang, D. H. Ahn, J. S. Cho, S. H. Chung, I. J. Park, M. R. Kim, H. J. Kim, Y. K. Kim, H. N. Lee, J. J. Yang, D. H. Ahn, J. S. Cho, S. H. Chung, I. J. Park, M. R. Kim, H. J. |
|---|---|
| author |
Kim, Y. K. Kim, H. N. Lee, J. J. Yang, D. H. Ahn, J. S. Cho, S. H. Chung, I. J. Park, M. R. Kim, H. J. |
| spellingShingle |
Kim, Y. K. Kim, H. N. Lee, J. J. Yang, D. H. Ahn, J. S. Cho, S. H. Chung, I. J. Park, M. R. Kim, H. J. Journal of Clinical Oncology Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line Cancer Research Oncology |
| author_sort |
kim, y. k. |
| spelling |
Kim, Y. K. Kim, H. N. Lee, J. J. Yang, D. H. Ahn, J. S. Cho, S. H. Chung, I. J. Park, M. R. Kim, H. J. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7575 <jats:p> 7575 </jats:p><jats:p> Background: IL-10 is an anti-inflammatory cytokine inhibiting T<jats:sub>h1</jats:sub> functions, which may facilitate tumor escape from the immune response. Among the various IL-10 promoter genes, the IL-10–1082G, -819C and -592C alleles were reported to be associated with high serum IL-10 level. Methods: In present study, we studied the frequency of these 3 alleles and their influence to the clinical outcome in 50 DLBCL patients treated with 8 cycles of R (Rituximab, 375 mg/m<jats:sup>2</jats:sup> on day 1 of each cycle)-CHOP every 3 weeks. Results: 50 patients with newly diagnosed DLBCL were included and all of them represented CD20 positivity. At diagnosis, median age was 60 (19∼85) and 24 (48%), 14 (28%), 8 (16%) and 4 (8%) patients belonged to the low, low-intermediate, high-intermediate and high risk group according to IPI reports, retrospectively. Of 50 patients, 8 (16%), 19 (38%) and 22 (44%) were found to carry IL-10–1082G, -819C and -592C alleles, retrospectively. As compared with -1082AA genotype, -1082G allele (GA/GG) failed to show better outcome (eg. higher CR or longer progression-free survival, PFS) after 8 cycles of R-CHOP. Further, patients with -819C or -592C alleles were not able to affect the response rates (CR or PR) compared with -819TT or -592AA genotype. On the other hand, the PFS was significantly shorter in patients carrying -819C allele than TT genotype (13.9 vs 26.9 ms, p<0.01). PFS also decreased in -592C allele compared with AA genotype (15.2 vs 26.5 ms, p<0.05). Of 30 patients with bcl<jats:sub>2</jats:sub> positivity, patients carrying -819C alleles also showed significant lower PFS than TT genotype (12.4 vs 16.1 ms, p<0.05). In multivariate analysis including IPI, stage, IL-10–1082G, -819C and -592C allele frequencies, -819C allele remained as an independent prognostic factor predicting shorter PFS (RR=3.6, p<0.05). In a haplotype analysis, patients carrying ATA/ATA showed significant longer PFS than in other haplotypes (p<0.05). Conclusions: It is still a matter of debate to manage the DLBCL patients with refractory or progressive disease. This study suggests that the detection of IL-10 gene promoter polymorphism such as -819C allele helps us to predict the patients with poor prognosis and to establish a stratified treatment plan in DLBCL patients. </jats:p><jats:p> No significant financial relationships to disclose. </jats:p> Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2006.24.18_suppl.7575 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNi4yNC4xOF9zdXBwbC43NTc1 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNi4yNC4xOF9zdXBwbC43NTc1 |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Society of Clinical Oncology (ASCO), 2006 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2006 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
kim2006interleukin10promotergenepolymorphism819cassociatedwithpoortreatmentoutcomeindlbclpatientstreatedwith8cyclesofrchopasafirstline |
| publishDateSort |
2006 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line |
| title_unstemmed |
Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line |
| title_full |
Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line |
| title_fullStr |
Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line |
| title_full_unstemmed |
Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line |
| title_short |
Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line |
| title_sort |
interleukin-10 promoter gene polymorphism (-819*c) associated with poor treatment outcome in dlbcl patients treated with 8 cycles of r-chop as a first line |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7575 |
| publishDate |
2006 |
| physical |
7575-7575 |
| description |
<jats:p> 7575 </jats:p><jats:p> Background: IL-10 is an anti-inflammatory cytokine inhibiting T<jats:sub>h1</jats:sub> functions, which may facilitate tumor escape from the immune response. Among the various IL-10 promoter genes, the IL-10–1082G, -819C and -592C alleles were reported to be associated with high serum IL-10 level. Methods: In present study, we studied the frequency of these 3 alleles and their influence to the clinical outcome in 50 DLBCL patients treated with 8 cycles of R (Rituximab, 375 mg/m<jats:sup>2</jats:sup> on day 1 of each cycle)-CHOP every 3 weeks. Results: 50 patients with newly diagnosed DLBCL were included and all of them represented CD20 positivity. At diagnosis, median age was 60 (19∼85) and 24 (48%), 14 (28%), 8 (16%) and 4 (8%) patients belonged to the low, low-intermediate, high-intermediate and high risk group according to IPI reports, retrospectively. Of 50 patients, 8 (16%), 19 (38%) and 22 (44%) were found to carry IL-10–1082G, -819C and -592C alleles, retrospectively. As compared with -1082AA genotype, -1082G allele (GA/GG) failed to show better outcome (eg. higher CR or longer progression-free survival, PFS) after 8 cycles of R-CHOP. Further, patients with -819C or -592C alleles were not able to affect the response rates (CR or PR) compared with -819TT or -592AA genotype. On the other hand, the PFS was significantly shorter in patients carrying -819C allele than TT genotype (13.9 vs 26.9 ms, p<0.01). PFS also decreased in -592C allele compared with AA genotype (15.2 vs 26.5 ms, p<0.05). Of 30 patients with bcl<jats:sub>2</jats:sub> positivity, patients carrying -819C alleles also showed significant lower PFS than TT genotype (12.4 vs 16.1 ms, p<0.05). In multivariate analysis including IPI, stage, IL-10–1082G, -819C and -592C allele frequencies, -819C allele remained as an independent prognostic factor predicting shorter PFS (RR=3.6, p<0.05). In a haplotype analysis, patients carrying ATA/ATA showed significant longer PFS than in other haplotypes (p<0.05). Conclusions: It is still a matter of debate to manage the DLBCL patients with refractory or progressive disease. This study suggests that the detection of IL-10 gene promoter polymorphism such as -819C allele helps us to predict the patients with poor prognosis and to establish a stratified treatment plan in DLBCL patients. </jats:p><jats:p> No significant financial relationships to disclose. </jats:p> |
| container_issue |
18_suppl |
| container_start_page |
7575 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
24 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792326173462626307 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T12:17:17.327Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Interleukin-10+promoter+gene+polymorphism+%28-819%2AC%29+associated+with+poor+treatment+outcome+in+DLBCL+patients+treated+with+8+cycles+of+R-CHOP+as+a+first+line&rft.date=2006-06-20&genre=article&issn=1527-7755&volume=24&issue=18_suppl&spage=7575&epage=7575&pages=7575-7575&jtitle=Journal+of+Clinical+Oncology&atitle=Interleukin-10+promoter+gene+polymorphism+%28-819%2AC%29+associated+with+poor+treatment+outcome+in+DLBCL+patients+treated+with+8+cycles+of+R-CHOP+as+a+first+line&aulast=Kim&aufirst=H.+J.&rft_id=info%3Adoi%2F10.1200%2Fjco.2006.24.18_suppl.7575&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792326173462626307 |
| author | Kim, Y. K., Kim, H. N., Lee, J. J., Yang, D. H., Ahn, J. S., Cho, S. H., Chung, I. J., Park, M. R., Kim, H. J. |
| author_facet | Kim, Y. K., Kim, H. N., Lee, J. J., Yang, D. H., Ahn, J. S., Cho, S. H., Chung, I. J., Park, M. R., Kim, H. J., Kim, Y. K., Kim, H. N., Lee, J. J., Yang, D. H., Ahn, J. S., Cho, S. H., Chung, I. J., Park, M. R., Kim, H. J. |
| author_sort | kim, y. k. |
| container_issue | 18_suppl |
| container_start_page | 7575 |
| container_title | Journal of Clinical Oncology |
| container_volume | 24 |
| description | <jats:p> 7575 </jats:p><jats:p> Background: IL-10 is an anti-inflammatory cytokine inhibiting T<jats:sub>h1</jats:sub> functions, which may facilitate tumor escape from the immune response. Among the various IL-10 promoter genes, the IL-10–1082G, -819C and -592C alleles were reported to be associated with high serum IL-10 level. Methods: In present study, we studied the frequency of these 3 alleles and their influence to the clinical outcome in 50 DLBCL patients treated with 8 cycles of R (Rituximab, 375 mg/m<jats:sup>2</jats:sup> on day 1 of each cycle)-CHOP every 3 weeks. Results: 50 patients with newly diagnosed DLBCL were included and all of them represented CD20 positivity. At diagnosis, median age was 60 (19∼85) and 24 (48%), 14 (28%), 8 (16%) and 4 (8%) patients belonged to the low, low-intermediate, high-intermediate and high risk group according to IPI reports, retrospectively. Of 50 patients, 8 (16%), 19 (38%) and 22 (44%) were found to carry IL-10–1082G, -819C and -592C alleles, retrospectively. As compared with -1082AA genotype, -1082G allele (GA/GG) failed to show better outcome (eg. higher CR or longer progression-free survival, PFS) after 8 cycles of R-CHOP. Further, patients with -819C or -592C alleles were not able to affect the response rates (CR or PR) compared with -819TT or -592AA genotype. On the other hand, the PFS was significantly shorter in patients carrying -819C allele than TT genotype (13.9 vs 26.9 ms, p<0.01). PFS also decreased in -592C allele compared with AA genotype (15.2 vs 26.5 ms, p<0.05). Of 30 patients with bcl<jats:sub>2</jats:sub> positivity, patients carrying -819C alleles also showed significant lower PFS than TT genotype (12.4 vs 16.1 ms, p<0.05). In multivariate analysis including IPI, stage, IL-10–1082G, -819C and -592C allele frequencies, -819C allele remained as an independent prognostic factor predicting shorter PFS (RR=3.6, p<0.05). In a haplotype analysis, patients carrying ATA/ATA showed significant longer PFS than in other haplotypes (p<0.05). Conclusions: It is still a matter of debate to manage the DLBCL patients with refractory or progressive disease. This study suggests that the detection of IL-10 gene promoter polymorphism such as -819C allele helps us to predict the patients with poor prognosis and to establish a stratified treatment plan in DLBCL patients. </jats:p><jats:p> No significant financial relationships to disclose. </jats:p> |
| doi_str_mv | 10.1200/jco.2006.24.18_suppl.7575 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNi4yNC4xOF9zdXBwbC43NTc1 |
| imprint | American Society of Clinical Oncology (ASCO), 2006 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2006 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T12:17:17.327Z |
| match_str | kim2006interleukin10promotergenepolymorphism819cassociatedwithpoortreatmentoutcomeindlbclpatientstreatedwith8cyclesofrchopasafirstline |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 7575-7575 |
| publishDate | 2006 |
| publishDateSort | 2006 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Kim, Y. K. Kim, H. N. Lee, J. J. Yang, D. H. Ahn, J. S. Cho, S. H. Chung, I. J. Park, M. R. Kim, H. J. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7575 <jats:p> 7575 </jats:p><jats:p> Background: IL-10 is an anti-inflammatory cytokine inhibiting T<jats:sub>h1</jats:sub> functions, which may facilitate tumor escape from the immune response. Among the various IL-10 promoter genes, the IL-10–1082G, -819C and -592C alleles were reported to be associated with high serum IL-10 level. Methods: In present study, we studied the frequency of these 3 alleles and their influence to the clinical outcome in 50 DLBCL patients treated with 8 cycles of R (Rituximab, 375 mg/m<jats:sup>2</jats:sup> on day 1 of each cycle)-CHOP every 3 weeks. Results: 50 patients with newly diagnosed DLBCL were included and all of them represented CD20 positivity. At diagnosis, median age was 60 (19∼85) and 24 (48%), 14 (28%), 8 (16%) and 4 (8%) patients belonged to the low, low-intermediate, high-intermediate and high risk group according to IPI reports, retrospectively. Of 50 patients, 8 (16%), 19 (38%) and 22 (44%) were found to carry IL-10–1082G, -819C and -592C alleles, retrospectively. As compared with -1082AA genotype, -1082G allele (GA/GG) failed to show better outcome (eg. higher CR or longer progression-free survival, PFS) after 8 cycles of R-CHOP. Further, patients with -819C or -592C alleles were not able to affect the response rates (CR or PR) compared with -819TT or -592AA genotype. On the other hand, the PFS was significantly shorter in patients carrying -819C allele than TT genotype (13.9 vs 26.9 ms, p<0.01). PFS also decreased in -592C allele compared with AA genotype (15.2 vs 26.5 ms, p<0.05). Of 30 patients with bcl<jats:sub>2</jats:sub> positivity, patients carrying -819C alleles also showed significant lower PFS than TT genotype (12.4 vs 16.1 ms, p<0.05). In multivariate analysis including IPI, stage, IL-10–1082G, -819C and -592C allele frequencies, -819C allele remained as an independent prognostic factor predicting shorter PFS (RR=3.6, p<0.05). In a haplotype analysis, patients carrying ATA/ATA showed significant longer PFS than in other haplotypes (p<0.05). Conclusions: It is still a matter of debate to manage the DLBCL patients with refractory or progressive disease. This study suggests that the detection of IL-10 gene promoter polymorphism such as -819C allele helps us to predict the patients with poor prognosis and to establish a stratified treatment plan in DLBCL patients. </jats:p><jats:p> No significant financial relationships to disclose. </jats:p> Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line Journal of Clinical Oncology |
| spellingShingle | Kim, Y. K., Kim, H. N., Lee, J. J., Yang, D. H., Ahn, J. S., Cho, S. H., Chung, I. J., Park, M. R., Kim, H. J., Journal of Clinical Oncology, Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line, Cancer Research, Oncology |
| title | Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line |
| title_full | Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line |
| title_fullStr | Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line |
| title_full_unstemmed | Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line |
| title_short | Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line |
| title_sort | interleukin-10 promoter gene polymorphism (-819*c) associated with poor treatment outcome in dlbcl patients treated with 8 cycles of r-chop as a first line |
| title_unstemmed | Interleukin-10 promoter gene polymorphism (-819*C) associated with poor treatment outcome in DLBCL patients treated with 8 cycles of R-CHOP as a first line |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7575 |